Aberrant expression of CD133 and musashi-1 in preneoplastic and neoplastic human oral squamous epithelium and their correlation with clinicopathological factors

Head and Neck

Volumn 34, Issue 8, 2012, Pages 1129-1135

  Ravindran, Gokulan ^a   Devaraj, Halagowder ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

cancer stem cells; CD133; Musashi 1; oral squamous cell carcinoma

Indexed keywords

CD133 ANTIGEN; MUSASHI 1; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NERVE TISSUE PROTEINS; PEPTIDES; PRECANCEROUS CONDITIONS; RNA-BINDING PROTEINS;

EID: 84864286876     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21896     Document Type: Article

References (44)

1. Warnakulasuriya S,. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-316.
2. Horisawa K, Imai T, Okano H, Yanagawa H,. The Musashi family RNA-binding proteins in stem cells. BioMol Concepts 2010; 1: 59-66.
3. Schulenburg A, Cech P, Herbacek I, et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 2007; 213: 152-160.
4. Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001; 34: 1-7.
5. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F,. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007; 13: 823-832.
6. Shu HJ, Saito T, Watanabe H, et al. Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun 2002; 293: 150-154.
7. Ye F, Zhou C, Cheng Q, Shen J, Chen H,. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008; 8: 108.
8. Sanchez-Diaz PC, Burton TL, Burns SC, Hung JY, Penalva LO,. Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer 2008; 8: 280.
9. Sureban SM, May R, George RJ, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology 2008; 134: 1448-1458.
10. Wang X-Y, Penalva L, Yuan H, et al. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer 2010; 9: 221.
11. Imai T, Tokunaga A, Yoshida T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol 2001; 21: 3888-3900.
12. Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004; 23: 3444-3453.
13. Glazer RI, Wang XY, Yuan H, Yin Y,. Musashi1: a stem cell marker no longer in search of a function. Cell Cycle 2008; 7: 2635-2639.
14. Götte M, Greve B, Kelsch R, et al. The adult stem cell marker musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via notch-1 and p21(WAF1/CIP1). Int J Cancer 2011 [Epub ahead of print].
15. Fargeas CA, Fonseca A-V, Huttner WB, Corbeil D,. Prominin-1(CD133): from progenitor cells to human diseases. Future Lipidol 2006; 1: 213-225.
16. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021.
17. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012.
18. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99: 100-109.
19. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003; 100: 15178-15183.
20. Hermann PC, Huber SL, Herrier T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
21. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
22. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
23. Horst D, Kriegl L, Engel J, Kirchner T, Jung A,. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99: 1285-1289.
24. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008; 14: 4085-4095.
25. Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-1397.
26. Woo T, Okudela K, Mitsui H, et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2011; 4: 32-42.
27. Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85.
28. Cheng JX, Liu BL, Zhang X,. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 2009; 35: 403-408.
29. Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K,. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45: 633-639.
30. Kang FW, Wang K, Wu M, Wang ZL, Zhu Y, Min R,. Biological characteristics of CD133+ subpopulation in tongue squamous cell carcinoma Tca8113 cell line. Hua Xi Kou Qiang Yi Xue Za Zhi 2010; 28: 560-564.
31. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD,. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010; 289: 151-160.
32. Felthaus O, Ettl T, Gosau M, et al. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun 2011; 407: 28-33.
33. Damek-Poprawa M, Volgina A, Korostoff J, et al. Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res 2011; 90: 638-645.
34. Pindborg JJ, Reichart PA, Smith CJ, Van der Waal I,. Histological typing of cancer and precancer of the oral mucosa. Springer-Verlag 1997: Heidelberg.
35. Chatelain K, Phipper S, McCabe J, Teeters CA, O'Malley S, Kingsley K,. Cranberry and grape seed extracts inhibit the proliferative phenotype of oral squamous cell carcinomas. Evid Based Complement Alternat Med 2008; [Epub ahead of print].
36. Al-Hajj M,. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007; 19: 61-64.
37. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
38. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
39. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
40. Zhao P, Li Y, Lu Y,. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010; 10: 218.
41. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A,. Expression of the 'stem cell marker' CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008; 8: 48.
42. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009; 15 (18): 2258-2264.
43. Kanemura Y, Mori K, Sakakibara S, et al. Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation. 2001; 68: 141-152.
44. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF,. Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis 2010; 25: 17-23.